Table 3.

Comparison of IFNL4-ΔG/TT (rs368234815) and IFNL3 rs4803217 for genotype associations among African-American participants for association with response to treatment with pegylated interferon-alfa plus ribavirin, VIRAHEP-C and HALT-C Trial.

			Treatment Time Point
			Week 20/24*			End-of-Treatment			SVR
Variant	Genotype	N	Response Rate (%)	aOR	p-value	Response Rate (%)	aOR	p-value	Response Rate (%)	aOR	p-value
VIRAHEP-C (n = 170)**
IFNL4-ΔG/TT	ΔG/ΔG	71	35.2	Ref.		32.4	Ref.		21.1	Ref.
	ΔG/TT	83	55.4	2.81	0.004	44.6	1.88	0.07	31.3	2.01	0.08
	TT/TT	16	68.8	5.10	0.01	56.3	2.93	0.07	43.8	3.28	0.05
	Additive			2.48	0.001		1.77	0.03		1.87	0.03
rs4803217	T/T	56	39.3	Ref.		35.7	Ref.		25.0	Ref.
	T/G	94	51.1	2.01	0.06	41.5	1.53	0.25	28.7	1.53	0.3
	G/G	20	60.0	3.02	0.05	50.0	2.12	0.17	35.0	2.01	0.24
	Additive			1.81	0.03		1.47	0.14		1.44	0.20
HALT-C Trial (n = 142)
IFNL4-ΔG/TT	ΔG/ΔG	64	9.4	Ref.		7.8	Ref.		3.1	Ref.
	ΔG/TT	70	18.6	3.38	0.047	14.3	2.70	0.13	8.6	4.41	0.13
	TT/TT	8	50.0	22.74	0.002	37.5	13.58	0.01	25.0	24.24	0.02
	Additive			4.29	0.002		3.38	0.01		4.86	0.02
rs4803217	T/T	59	10.2	Ref.		8.5	Ref.		3.4
	T/G	66	18.2	3.12	0.07	13.6	2.56	0.16	7.6	4.32	0.14
	G/G	17	29.4	6.43	0.03	23.5	5.04	0.05	17.6	10.66	0.04
	Additive			2.59	0.01		2.27	0.04		3.21	0.03

^*In VIRAHEP-C response is at 24 weeks after initiation of treatment; in HALT-C response is at 20 weeks after initiation of treatment

^**One subject is lost from the adjusted analyses for VIRAHEP-C due to missing data for fibrosis

SVR, sustained virological response; aOR, odds ratio adjusted for pre-treatment HCV RNA level and fibrosis stage